Noopept
Also known as: GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam
Overview
Noopept (GVS-111) is a synthetic dipeptide-derived nootropic compound that acts as a prodrug for cycloprolylglycine (CPG), an endogenous neuropeptide that modulates AMPA receptor function and has neurotrophic activity. Developed in Russia in the 1990s, Noopept is estimated to be approximately 1000 times more potent by weight than piracetam (though this comparison is mechanistically distinct). It is available as a prescription medication in Russia for cognitive disorders and widely used globally as a cognitive enhancer.
Mechanism of Action
After oral absorption, Noopept is cleaved to release cycloprolylglycine (CPG), which acts as an AMPA receptor modulator (ampakine activity) that enhances glutamatergic neurotransmission and promotes LTP (long-term potentiation). Additionally, Noopept stimulates BDNF and NGF expression in the hippocampus and cortex via TrkB receptor pathway sensitization. It also demonstrates anxiolytic activity through GABA-A receptor modulation and reduces oxidative stress in neuronal tissues. Alpha wave EEG activity is increased, associated with relaxed attention.
Potential Benefits
- Cognitive enhancement including memory consolidation and recall
- BDNF and NGF elevation in hippocampus
- Anxiolytic effects without sedation
- Neuroprotection in ischemia and excitotoxicity models
- Enhanced verbal memory and learning in clinical studies
- High oral bioavailability with rapid CNS penetration
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 10 mg 1x daily |
| Intermediate | 10 mg 2x daily (morning/early afternoon) |
| Advanced | 10 mg 3x daily (do not exceed 30 mg) |
| Cycle Duration | 4-12 weeks with breaks |
Not a peptide — a proline-containing dipeptide prodrug (N-phenylacetyl-L-prolylglycine ethyl ester) converted to cycloprolylglycine. Russian racetam-class nootropic.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral (capsule/tablet) Good — prodrug rapidly absorbed
Standard route. Take with or without food.
Sublingual (powder) Higher — bypasses first-pass
Commonly used form. Hold powder under tongue 30-60 seconds.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Noopept:
Nootropic Stack
Classic nootropic combination — Noopept 10-20 mg for BDNF/NGF, Alpha-GPC 300 mg for acetylcholine, PS 100 mg for membrane support.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store capsules/tablets at room temperature in a dry, dark place. Liquid formulations refrigerated. |
|---|
Oral peptide — no reconstitution required. Follow product label for storage specifics.
Need exact syringe measurements?
Amino Acid Sequence
N-phenylacetyl-L-prolyl-glycine ethyl ester (prodrug for CPG dipeptide)
Side Effects & Safety
- Generally well-tolerated at recommended doses
- Headache (may indicate choline deficiency)
- Irritability or anxiety at high doses
- Mild nausea
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~30-60 minutes (parent); cycloprolylglycine metabolite longer |
|---|---|
| Storage | Store at room temperature (15-25°C) in a dry, dark place. Keep tightly closed. Do not refrigerate capsules. |
Synergistic Compounds
The following compounds have been studied alongside Noopept for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.